OTCM
ATXI
Market cap1mUSD
Oct 08, Last price
0.43USD
1D
-4.28%
1Q
34.82%
IPO
-100.00%
Name
Avenue Therapeutics Inc
Chart & performance
P/E
—
P/S
1.01
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.27%
Rev. gr., 5y
%
Revenues
1m
Net income
-3m
L-75.03%
CFO
-2m
L-79.69%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Key people
Jay Kranzler
Non-Executive Chairman of the Board · since 2023
Alexandra Maclean
Chief Executive Officer, Director · since 2023
Interim Chief Financial Officer, Chief Operating Officer · since 2022
Director · since 2023
Independent Director · since 2022
Neil Herskowitz
Independent Director · since 2015
Independent Director · since 2021
Legal address
C/O Incorporating Services, Ltd.
3500 South DuPont Highway
Dover, DE 19901
US
3500 South DuPont Highway
Dover, DE 19901
US
Headquarters
9th Floor
2 Gansevoort Street
New York, NY 10014
US
2 Gansevoort Street
New York, NY 10014
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||